NovAccess Global Inc.

Equities

XSNX

US67001N1072

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 14:52:21 2024-06-28 EDT			5-day change	1st Jan Change
0.0082 ^USD	-18.00%		-18.00%	-59.20%

05-31	NovAccess Global Inc. announced that it has received $0.009 million in funding	CI
05-21	NovAccess Global Inc. Files Patent with Cedars-Sinai to Advance Its Brain Cancer Fighting Vaccine Platform	CI

Xsunx, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2019

January 24, 2020 at 04:33 pm

XsunX, Inc. announced earnings results for the first quarter ended December 31, 2019. For the first quarter, the company announced sales was USD 200,386 compared to USD 386,736 a year ago. Operating loss was USD 77,637 compared to USD 22,414 a year ago. Net loss was USD 101,664 compared to net income of USD 1.406 million a year ago.

Latest news about NovAccess Global Inc.

NovAccess Global Inc. announced that it has received $0.009 million in funding	05-30	CI
NovAccess Global Inc. Files Patent with Cedars-Sinai to Advance Its Brain Cancer Fighting Vaccine Platform	05-21	CI
NovAccess Global Inc. acquired 18.60% stake in Fendix Media Ltd from David Sumner for $0.12 million.	05-16	CI
NovAccess Global Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-15	CI
NovAccess Global Inc. announced that it has received $0.1053 million in funding from AJB Capital Investments LLC	05-12	CI
NovAccess Global Inc. announced that it has received $0.0265 million in funding from AJB Capital Investments LLC	04-28	CI
NovAccess Global Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-27	CI
NovAccess Global Inc. announced that it has received $0.1 million in funding from AJB Capital Investments LLC	02-26	CI
NovAccess Global Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	02-09	CI
NovAccess Global Inc. Appoints Roscoe M. Moore, Jr. to Scientific Advisory Board	11-10	CI
NovAccess Global Inc. announced that it expects to receive $10.68 million in funding from Sumner Capital Pty Ltd.	23-08-31	CI
NovAccess Global Inc. announced that it expects to receive $0.055 million in funding	23-08-15	CI
NovAccess Global Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-11	CI
NovAccess Global Inc. Partners with BCN Biosciences to Expand Immunotherapy Platform	23-07-27	CI
NovAccess Global Inc. announced that it has received $0.055 million in funding from 1800 Diagonal Lending, LLC	23-06-19	CI
NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine Division	23-06-16	CI
NovAccess Global Inc. Enters into a Letter Agreement with AJB Capital Investments, LLC	23-06-12	CI
NovAccess Global Inc. Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalised Healthcare Therapies	23-06-01	CI
NovAccess Global Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-15	CI
NovAccess Global Inc. announced that it has received $0.05425 million in funding from 1800 Diagonal Lending, LLC	23-04-27	CI
NovAccess Global Inc. announced that it expects to receive $0.05425 million in funding from 1800 Diagonal Lending, LLC	23-04-23	CI
NovAccess Global Inc. announced that it has received $0.07925 million in funding from 1800 Diagonal Lending, LLC	23-04-10	CI
NovAccess Global Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-02-14	CI
NovAccess Global Inc. announced that it has received $0.265 million in funding	23-02-08	CI
NovAccess Global Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	23-01-10	CI

Chart NovAccess Global Inc.

Duration

Period

More charts

Company Profile

NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patientâs own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patientâs tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NOVACCESS GLOBAL INC.	-59.20%	617K
LONZA GROUP AG	+38.65%	39.1B
IQVIA HOLDINGS INC.	-8.62%	38.76B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	31.24B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.9B
CELLTRION, INC.	-13.50%	25.8B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.06B
MEDPACE HOLDINGS, INC.	+34.36%	13.12B
BIO-TECHNE CORPORATION	-7.14%	11.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.61%	10.68B

Other Biotechnology & Medical Research